Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Carcinoma, Hepatocellular 4Carcinoma, Renal Cell 3Stomach Neoplasms 2Solid Tumors 2Melanoma 2Carcinoma 2Breast Neoplasms 2Seminoma 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Fibrosis 1Colorectal Neoplasms 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × ARQ 197 × Clear all
NCT01152645 2017-03-15

ARQ 197-004

Kyowa Kirin Co., Ltd.

Phase 2 Completed
31 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01070290 2014-01-07

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Withdrawn
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡